Sidvim LifeSciences Private Limited

  Contents Patent portfolio of Embio Limited General information Evonik and Laxxon to Produce More Effective 3D Printed Pills Medichem’s Stampa Takes Lead at Medicines for Europe Intellectual Property Canagliflozin composition patent revoked by Board of Appeals at European Patent Office Corrigendum Patent portfolio of Embio Limited In Sidvim, we analyse patent portfolio of many companies, last week we analysed patent portfolio of Embio Limited. As per their website, Embio was incorporated in 1986, a leading global player in the domain of controlled substances and chiral molecules manufactured through bio-transformation.  Here Glimpse of their patent applications are as below. As one would notice, many patent applications are around control substances and chiral separations.  Sr Family number Publication Date Patent relates to  SIDVIM comments 1 WO2021176381A1 2021-09-10 1-(1-naphthyl)ethyl amine is an intermediate for many APIs such as Upadacitinib, cinacalcet.  Patent ap

  Contents FDA approvals in February 2022 General information Automated chemistry: The machines that can discover new drugs Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into a new class of cancer drug Intellectual Property Naproxen and Esomeprazole Magnesium delayed-release tablets (Vimovo) FDA approvals in February 2022 FDA approved PYRUKYND in February 2022.  The active ingredient of PYRUKYND is mitapivat, a pyruvate kinase activator, present as mitapivat sulfate. The chemical name of mitapivat sulfate is 8-quinolinesulfonamide, N-[4-[[4 (cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-, sulfate, hydrate (2:1:3) Mitapivat is a pyruvate kinase activator that acts by allosterically binding to the pyruvate kinase tetramer and increasing pyruvate kinase (PK) activity. The red blood cell (RBC) form of pyruvate kinase (PK-R) is mutated in PK deficiency, which leads to reduced adenosine triphosphate (ATP), shortened RBC lifespan, and chronic haemoly

  Contents FDA approvals in January 2022 General information How the Indian Pharmaceutical Industry is planning to grow in 2022 Supreme Court: Pharma freebies for doctors' immoral or illegal Intellectual Property GSK vs Teva on Skinny label or label cave out issue FDA approvals in January 2022 We analyse FDA approvals every month. FDA approved daridorexant (QUVIVIQ) in January 2022. QUVIVIQ contains daridorexant, an orexin receptor antagonist. It is a medication used for the treatment of insomnia. The chemical name of daridorexant hydrochloride is (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5 methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride. Daridorexant HCl is a white to light yellowish powder that is very slightly soluble in water.  The synthesis of daridorexant, is described in WO2013/182972 and W02015/083094. Crystalline salt forms of daridorexant are disclosed in WO2015/083071; and crystalline forms of daridorexant in